anti-CD22 CAR-T therapy / Wuhan Bio–Raid - LARVOL DELTA

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. (PubMed, Front Immunol) - "The median doses of CD22 and CD19 CAR T cell infusions were 4.1 × 10/kg and 4.0 × 10/kg, respectively. Both the estimated 1-year progression-free and overall survival rates were 55.6%. Our preliminary results indicated that salvage therapy with CD19/CD22 CAR T cell infusion alone and that in combination with ASCT are effective in treating some adult patients with r/r Burkitt lymphoma."

Journal • Bone Marrow Transplantation • Burkitt Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Oncology • Transplantation • CD19 • CD22

CD19/CD22 CAR T cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas: Combined CAR T Cell Therapy and Transplantation. (PubMed, Transplant Cell Ther) - "The high durable CR rates and favorable safety profiles supported the strong potential of the HDT-ASCT plus CD19/CD22 CAR-T cell cocktail therapy for the suboptimal group of R/R aggressive B-NHL who are less sensitive or failed to salvage chemotherapy. These early data were encouraging and informative to future trials to further test the efficacy and safety of the ASCT plus CAR-T therapy in a larger population."

CAR T-Cell Therapy • Clinical • Journal • Bone Marrow Transplantation • Hematological Malignancies • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19 • CD22 • FDG PET

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Wuhan Union Hospital, China

Clinical • New P1 trial